magrolimab + pembrolizumab

Magrolimab + pembrolizumab is an investigational combination therapy consisting of two monoclonal antibodies developed for cancer treatment. Magrolimab is a monoclonal antibody that targets and blocks CD47, a "don't eat me" signal commonly overexpressed on cancer cells, leading to enhanced macrophage-mediated phagocytosis of tumor cells. Pembrolizumab is a humanized IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor on lymphocytes, blocking its interaction with PD-L1 and PD-L2 to release immune checkpoint inhibition, thereby enhancing anti-tumor immune responses. The combination is under clinical investigation for relapsed or refractory classic Hodgkin lymphoma and head and neck squamous cell carcinoma, aiming to leverage complementary immunotherapeutic mechanisms[1][3][5].